Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is a heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, clinical biochemistry, rheumatology, advanced therapies or transfusional medicine. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

268

total

1598

impact factor

5.96

average impact factor

Group Leader: Ricardo Pujol Borrell

team

zoom

download

COVID-19 had an important impact in the research of group during 2020. As IL-6 became one of the reference biomarkers for COVID-19, the immunology group with the core laboratory organized a biobank of sera samples linked to a database that has contributed to several multidisciplinary projects reflected in articles, some already published. The most notorious is the contribution to the identification of the first gene mutations associated to severe COVID (PMID, 32972996) and to the unexpected detection of IFN-alpha autoantibodies also in severe cases (PMID 32972996). This experience has further increase interest of the group in the immunology of host?pathogen interaction, a line that in 2019 already produced a watershed paper in collaboration with the ICU group and the epigenetic group of Dr Ballestar at the Carreras Research institute (Lorente Sorolla et al, 2019). Withstanding these new activities, research on primary immunodeficiencies was maintained, and the projects on autoimmunity resumed in the last quarter of 2020.

23

total

168

impact factor

7^.30

average impact factor

SELECTED ARTICLES

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D’Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians (Roger Colobran among the authors); COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL.
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Science. 2020; 23;370:eabd4585.
DOI: 10.1126/science.abd4585
IF: 41.8 – Q1
Caronna E, Ballvé A, Llauradó A, Gallardo VJ, María Ariton D, Lallana S, Maza SL, M. O. Gadea, L. Quibus, J. L. Restrepo, M. Rodrigo-Gisbert, A. Vilaseca, M. Hernández-González, M. Martínez- Gallo, A. Alpuente, M. Torres-Ferrus, R. Pujol-Borrell, J. Alvarez-Sabin, and P. Pozo-Rosich.
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution.
Cephalalgia 2020; 40: 1410–1421.4.
DOI: 10.1177/0333102420965157
IF: 6.292 – Q1
Rivière, J. G., C. Franco-Jarava, M. Martínez-Gallo, A. Aguiló-Cucurull, L. Blasco-Pérez, I. Paramonov, M. Antolín, A. Martín-Nalda, P. Soler-Palacín, and R. Colobran.
Uncovering Low-Level Maternal Gonosomal Mosaicism in X-Linked Agammaglobulinemia: Implications for Genetic Counseling.
Front. Immunol. 2020; 11: 46.
DOI: 10.3389/fimmu.2020.00046
IF: 7.561 – Q1
Viñas-Giménez, L., N. Padilla, L. Batlle-Masó, F. Casals, J. G. Rivière, M. Martínez-Gallo, X. de la Cruz, and R. Colobran.
FHLdb: A Comprehensive Database on the Molecular Basis of Familial Hemophagocytic Lymphohistiocytosis.
Front. Immunol. 2020; 11: 107.
DOI 10.3389/fimmu.2020.00107
IF: 7.561 – Q1
Riveiro-Barciela M, Labrador-Horrillo M Camps-Relats L, Gonzalez-Sans D, Ventura-Cots M, Terrones-Peinador M, Núñez-Conde A, Martínez-Gallo M, Hernández-González M, Anton A, González A, Pujol-Borrell R and Martínez-Valle F.
Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis.
PLoS One 2020: 15.2.
DOI: 10.1371/journal.pone.0244627
IF: 3.40 – Q2

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Ricardo Pujol Borrell

Research Areas